Screening and Screening Cascade Development

As a trusted and respected screening services CRO, we collaborate with university spinouts, start-ups, AI-driven innovators, and biotechnology and pharmaceutical companies to accelerate drug discovery. We efficiently screen small molecules, fragments, peptides, antibodies, antibody drug conjugates (ADCs), Protein Targeting Chimeras (PROTACs), molecular glues, and other modalities, enabling confident progression through the Design–Make–Test–Analyze (DMTA) cycle.

Our screening platforms are designed to generate robust, reproducible, and translationally relevant data, allowing you to triage compounds effectively and focus resources on your most promising drug candidates.

Supporting your drug discovery objectives

Achieve more from early discovery

With extensive experience developing cost effective, robust and scalable screening assays and screening cascades, it’s possible to rapidly progress your project through the hit finding and hit-to-lead stages of drug development.

Successful drug discovery depends on the ability to:

• Validate biological targets.
• Identify high-quality hits.
• Optimize leads through iterative testing.
• Reduce attrition before in vivo and clinical studies.

Our screening services are embedded within our wider Integrated Drug Discovery service (IDDS) framework, supporting efficient progression from discovery to development, an essential part of the DMTA cycle.

Working in partnership with you, our subject-matter experts leverage extensive experience to design and develop robust, fit-for-purpose assays for screening of candidate therapeutics.

• ADMET‍
• Computational chemistry
• Medicinal chemistry
• Proteins
• Biophysics
• Structural biology
• In vivo assays

Whether you require stand-alone screening support or a fully integrated solution, we will tailor our services to ensure that you achieve your drug discovery goals.

Overcoming Common Screening Challenges

Organizations developing new therapeutics often face scientific, operational, and resource constraints when establishing effective screening programs. Our integrated screening services are designed to overcome these barriers and deliver high-confidence progression through early discovery.

Screening capabilities

Comprehensive assay platforms

We develop, optimize, and run robust and repeatable assays to reliably screen 10s to 10000s of therapeutics assays, across multiple formats and biological systems. This enables you to identify successful candidates that can be taken forward for hit-to-lead, lead optimization and candidate selection:

• Biochemical assays - HTRF, TR-FRET, FP, AlphaLISA, Luminescent, Enzymatic.
• Cell-based screening assays - cytotoxicity, reporter, target engagement, phenotypic.
• Biophysical assays - SPR, DSF, ITC.
• Bespoke mechanism of action studies.

Accelerate your screening strategy

Our screening and screening cascade development services are designed to de-risk early discovery, strengthen hit identification, and accelerate lead optimization, empowering you to progress only the most promising candidates toward clinical success.

Screening cascade development

Specializing in building robust customized screening cascades that support confident decision-making throughout discovery, our scientists will work with you to develop:

1. Primary high-throughput screening.
2. Secondary and orthogonal validation.
3. Cellular and functional confirmation.
4. Mechanism of action studies.
5. SAR-driven screening loops.

Our approach focuses on delivering actionable insight, not just raw data. Each cascade is designed to maximize data quality, minimize false positives, and support rapid hit-to-lead progression.

Contact our team to discuss your screening requirements and discovery strategy.

From capability to impact: Screening services at Concept Life Sciences

Your integrated screening partner

Our depth of experience in assay development, high-throughput screening, and cascade design ensures your program benefits from:

• Proven screening workflows.
• Seamless integration with medicinal chemistry and ADMET.
• Scalable infrastructure.
• Strategic scientific support.

Helping you progress only the most promising candidates toward clinical success.

Screening FAQs

Q: How can your screening services accelerate our drug discovery program?

A: Our expert teams design and implement robust biochemical, cellular, and biophysical screening cascades. By rapidly developing and validating assays, we enable faster hit identification and high-throughput screening, reducing time to candidate selection.

Q: How do you ensure reliable and actionable screening data?

A: We prioritize assay robustness, reproducibility, and orthogonal validation. Our structured screening cascades, combined with quality-controlled data management, minimize false positives and deliver high-confidence datasets for informed decision-making.

Q: How do your services reduce cost and risk in early discovery?

A: By strategically selecting the most informative assays and integrating screening with medicinal chemistry and ADMET support, we reduce wasted experiments, accelerate hit-to-lead progression, and maximize value from your budget.

Q: Can your screening services scale as our pipeline grows?

A: Yes. Our platforms and workflows are designed to scale from focused validation assays to large high-throughput campaigns. We support both short-term projects and long-term integrated screening partnerships.

Q: How do you act as a strategic partner, not just a service provider?

A: Beyond executing assays, we provide consultation, data interpretation, and insights to guide decision-making. Our teams integrate seamlessly with client projects to optimize screening cascades, accelerate DMTA cycles, and ensure only the most promising candidates progress.